Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gynecologic Oncology
•
Vulvar Cancer
Is it reasonable to only treat the inguinal nodes and not the pelvic nodes in an unresectable cT1cN0 vulvar SCC at the clitoris?
What would be factors that would indicate the need to include the pelvic nodes?
Answer from: Radiation Oncologist at Community Practice
If lesion is superficial one can but if thick lesion based on drainage pattern would favor both inguinal region and lower pelvic nodes
Sign in or Register to read more
4715
Related Questions
How would you evaluate the role for adjuvant radiation in a very young female (20s) with a localized vulvar SCC, HPV independent, status post hemivulvectomy?
What dose would you use to treat unresectable basal cell carcinoma of the vulva?
How would you manage a bulky primary exophytic vulvar SqCC in a patient with uncontrolled but very long standing HIV disease?
Would you treat with extended field pelvic radiation for a patient with FIGO IIIC1 endometrial cancer who was found with isolated tumor cells (ITCs) on a single paraaortic sentinel lymph node?
Would you recommend surgery or stereotactic radiation therapy for a young woman with high-grade serous ovarian cancer presenting with a pelvic LN oligometastasis following maintenance therapy?
For a patient with locally current endometrial cancer whose disease had complete radiographic response to carboplatin, Taxol, and pembrolizumab, would you consider adding radiation therapy?
How would you evaluate the right inguinofemoral lymph nodes in a female patient in her 30s with a 4 mm midline SCC of the vulva (depth of invasion 1.45 mm) and a PET-positive enlarged left inguinal node, for whom you plan to debulk the left inguinofemoral lymph nodes?
With the addition of pembrolizumab following chemoradiation per KEYNOTE-A18, would you be less likely to treat the paraaortic chain prophylactically?
Between KEYNOTE A-18 and INTERLACE, for which patients would you recommend using one protocol over another?
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?